Core Insights - Nossger (Beijing) Pharmaceutical Technology Co., Ltd. reported a revenue of 380 million yuan for the first half of 2025, reflecting a year-on-year growth of 0.18% [1] - The net profit attributable to shareholders reached 61.1161 million yuan, up 4.45% year-on-year, with a basic earnings per share of 0.64 yuan, an increase of 4.92% [1] Business Performance - The company's core business focuses on the clinical CRO sector, providing a comprehensive drug clinical research service [2] - Revenue from the clinical trial site management services (SMO) was 129 million yuan, showing a significant growth of 31.23% with a gross margin of 33.67% [2] - Clinical trial operation services (CO) generated revenue of 149 million yuan with a gross margin of 28.78% [2] - Data management and statistical analysis services (DM/ST) achieved revenue of 50.4924 million yuan, maintaining a high gross margin of 48.15% [2] - R&D investment increased by 8.59% to 30.6726 million yuan, supporting business innovation and service capability enhancement [2] Strategic Development - The company aims to expand innovative services and accelerate global business development while maintaining a focus on human health [3] - Nossger has adjusted some fundraising projects, terminating the "Data Science Center Project" to optimize resource allocation [3] - The company has established a comprehensive risk response mechanism to address industry regulatory changes, intensified market competition, and operational challenges [3]